Reported about 15 hours ago
CRISPR Therapeutics has started generating sales from its first gene therapy, Casgevy, which has been approved for treating sickle cell disease. The company has ample cash reserves and a promising pipeline of multiple therapies currently in development. While investing in biotech carries risks, the potential for high returns exists if CRISPR successfully commercializes more therapies in the coming years. As the company's stock price has significantly dipped from its peak, long-term investors could see substantial gains if all goes well.
Source: YAHOO